Skip to main content
Premium Trial:

Request an Annual Quote

20/20 GeneSystems, Kodak Strike Protein-Analysis Partnership

NEW YORK, Dec. 10 — Eastman Kodak's scientific imaging division has struck a deal to market and distribute 20/20 GeneSystems' tool for multiplex protein analysis, the firms said on Monday.

 

20/20 GeneSystems' protein analysis technology, called P-FILM, works by multiplexing the technique of a Western blot, transferring separated proteins through a stacked sheaf of up to 10 membranes. Each one may then be individually treated with antibodies, allowing parallel analysis from one gel.

 

"Our technology offers a way to identify groups of proteins from one sample at the same time," said 20/20's CEO and founder Jonathan Cohen, whose company's technology will be resold or distributed by Kodak. "A lot of the people that run electrophoresis gels will buy film or use digital imaging instruments. It makes perfect sense to reach this particular group of customers," he added.

 

"More broadly," Cohen said, "Kodak is one of the most recognized brands in the world, and for us as a small 18-month old company to have that kind of brand recognition is extraordinarily powerful."

 

Further details of the partnership were not available.

 

The deal is the first step in a partnership that may have a significant future. The imaging giant is considering other deals with 20/20 GeneSystems that would involve marketing rights to many products the company is now developing from this core technology, including image analysis software, DNA and RNA electrophoresis gels, and rapid assays to identify bioterrorism agents.

 

20/20 GeneSystems, based in Rockville, Md., is also exploring partnerships with pharmaceutical companies to analyze human or animal tissue samples from drug candidate studies for protein activity, said Cohen.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.